Aldo Pezzuto1, Federico Cappuzzo2, Manolo D'Arcangelo2, Massimo Ciccozzi3, Luca Navarini4, Simone Guerrini5, Alberto Ricci5,6, Michela D'Ascanio5, Elisabetta Carico6. 1. Cardiovascular-Respiratory Sciences Department, Sant' Andrea Hospital-Sapienza University, Rome, Italy pezzutoaldo@libero.it. 2. Department of Oncoematology, AUSL della Romagna, Ravenna, Italy. 3. Department of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico, Rome, Italy. 4. Allergology, Immunology, Rheumatology Unit, Department of Medicine, University Campus Bio-Medico di Roma, Rome, Italy. 5. Cardiovascular-Respiratory Sciences Department, Sant' Andrea Hospital-Sapienza University, Rome, Italy. 6. Clinical and Molecular Medicine Department, Sant' Andrea Hospital-Sapienza University, Rome, Italy.
Abstract
BACKGROUND/AIM: Non-small cell lung cancer (NSCLC) is the leading cause of cancer death. Patients eligible for surgery have better overall survival rate than patients who are not eligible. We investigated the prognostic value of p16 in patients who underwent surgery for lung cancer, in association with other factors such as PD-L1 and Ki-67. MATERIALS AND METHODS: Expression of p16 was evaluated along with the presence of Ki-67 and PD-L1 in 256 NSCLC patients treated only surgically. RESULTS: Adenocarcinoma was the prevalent histotype (56%) followed by squamous cell (29%) and differentiation grade of 3 was the most common (60%). p16 was detected in 83 patients (30%): low positivity (<10% cells) was observed in 30 samples (11%) and high positivity (>10 % cells) in 53 patients (20%). Ki-67 was detected in 89 patients (34%) with mild positivity in 46 patients (10-25% cells), moderate positivity (26-75% cells) in 30 patients (11%), and high positivity (>75% cells) in 13 patients (5%). An influence of p16 expression (p<0.05) along with grading and staging on overall survival (OS) was found. The average OS was 36 months, but the OS increased up to 54 months when patients were stratified according to p16 expression levels. The stratification by staging showed a significant prognostic value for p16 at an early stage (p<0.014). CONCLUSION: p16 significantly influences prognosis, notably at an early stage, along with other variables such as grading and staging. Copyright
BACKGROUND/AIM: Non-small cell lung cancer (NSCLC) is the leading cause of cancer death. Patients eligible for surgery have better overall survival rate than patients who are not eligible. We investigated the prognostic value of p16 in patients who underwent surgery for lung cancer, in association with other factors such as PD-L1 and Ki-67. MATERIALS AND METHODS: Expression of p16 was evaluated along with the presence of Ki-67 and PD-L1 in 256 NSCLCpatients treated only surgically. RESULTS:Adenocarcinoma was the prevalent histotype (56%) followed by squamous cell (29%) and differentiation grade of 3 was the most common (60%). p16 was detected in 83 patients (30%): low positivity (<10% cells) was observed in 30 samples (11%) and high positivity (>10 % cells) in 53 patients (20%). Ki-67 was detected in 89 patients (34%) with mild positivity in 46 patients (10-25% cells), moderate positivity (26-75% cells) in 30 patients (11%), and high positivity (>75% cells) in 13 patients (5%). An influence of p16 expression (p<0.05) along with grading and staging on overall survival (OS) was found. The average OS was 36 months, but the OS increased up to 54 months when patients were stratified according to p16 expression levels. The stratification by staging showed a significant prognostic value for p16 at an early stage (p<0.014). CONCLUSION:p16 significantly influences prognosis, notably at an early stage, along with other variables such as grading and staging. Copyright